- Telsey Advisory Group analyst Dana Telsey reiterated a Market Perform rating on the shares of Designer Brands Inc (NYSE:DBI) and lowered the price target from $12 to $8.
- The company will report first-quarter results on Thursday, June 8, before the market opens.
- The analyst reduced estimates for 1Q23, to reflect anticipated consumer demand weakness brought on by continued macro headwinds across the broader retail landscape.
- The analyst expects EPS of $0.25, down from the previous estimate of $0.33, and sales to decline 8.6% Y/Y to $759 million.
- The analyst lowers the FY23 EPS estimate to $1.65 from $1.70, and sales to decline 4.1% Y/Y to $3.1 billion, down from the prior estimate of $3.21 billion.
- Given the top and bottom-line declines planned for FY23, DBI anticipates macro and inflationary pressures to persist through 1H before recovering in H2.
- The analyst added that while near-term pressures continue to impact DBI’s business, the company’s long-range plan remains intact.
- Price Action: DBI shares are trading higher by 6.77% at $6.87 on the last check Tuesday.
Biodexa Pharmaceuticals Presents Phase 2 Clinical Trial Results Of Its Newly-Licensed eRapa In Familial Adenomatous Polyposis Scheduled For Presentation At The 2024 Digestive Disease Week Annual Meeting; Reports Overall 83% Non-Progression Rate At 6 Mo…
Biodexa Pharmaceuticals PLC("Biodexa" or the "Company")Positive Statistically Significant Phase 2 Clinical Trial Results of Biodexa's Newly-licensed eRapa™ in Familial Adenomatous Polyposis (FAP) Scheduled for
